Atea Pharmaceuticals (AVIR) Cash from Financing Activities (2020 - 2026)

Atea Pharmaceuticals' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $257000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 174.06% year-over-year to $257000.0; the TTM figure through Mar 2026 stood at -$25.1 million (down 10830.87% YoY), while the FY2025 annual figure was -$25.7 million, down 9742.32% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $257000.0, up from -$11.3 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $257000.0 in Q1 2026, with the low at -$14.1 million in Q2 2025.
• The 5-year median for Cash from Financing Activities is $132000.0 (2022), against an average of -$2.5 million.
• The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities tumbled 9762.39% in 2025, then soared 174.06% in 2026.
• Atea Pharmaceuticals' Cash from Financing Activities stood at $147000.0 in 2022, then plunged by 37.41% to $92000.0 in 2023, then increased by 27.17% to $117000.0 in 2024, then sank by 9762.39% to -$11.3 million in 2025, then soared by 102.27% to $257000.0 in 2026.
• Business Quant data shows AVIR's Cash from Financing Activities at $257000.0 in Q1 2026, -$11.3 million in Q3 2025, and -$14.1 million in Q2 2025.